<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334330</url>
  </required_header>
  <id_info>
    <org_study_id>SCBCS025</org_study_id>
    <nct_id>NCT04334330</nct_id>
  </id_info>
  <brief_title>Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China</brief_title>
  <official_title>Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>wang shusen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of combination of palbociclib,
      trastuzumab and lapatinib with fulvestrant in ER positive，HER2-positive breast cancer
      patients with brain metastasis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 3, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate in the CNS</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Assess the response rate in the CNS by MRI according to modified Response Assessment in Neuro-Oncology Criteria Brain Metastasis (modified RANO-BM). Objective CNS response is defined as a 30% or greater volumetric reduction of CNS lesions in the absence of increased steroid use, progressive neurological symptoms, and progressive extra-CNS disease. All responses had to be confirmed 4 weeks after initial response. Radiological response was assessed every 8 weeks by MRI scan for CNS lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Determine the safety and tolerability of the study drug combination by evaluating number, frequency, and severity of adverse events using Common Terminology Criteria for Adverse Events version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>OS is defined as the time from treatment initiation until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>PFS is defined as the time from treatment initiation to documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Evaluate systemic ORR defined as partial response or complete response assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CNS progression</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to CNS progression will be defined as the time from treatment initiation to documented disease progression (modified RANO-BM criteria) in the CNS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radiotherapy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to radiotherapy is defined as the time from the date of inclusion to the date of event defined as the initiation of radiotherapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in cognitive function in patients receiving study drugs</measure>
    <time_frame>At baseline, 2 months and 4 months</time_frame>
    <description>Change in cognitive function will be assessed at baseline, 2 months and 4 months and will be collected using patient reported outcome questionnaires: Functional assessment of Cancer Therapy-Cognitive function Version 3.0 (Fact -Cog)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in quality of life in patients receiving study drug combination</measure>
    <time_frame>At baseline, 2 months and 4 months</time_frame>
    <description>Quality of life measures will be assessed at baseline, 2 months and 4 and will be collected using patient reported outcome questionnaires: Functional Assessment of Cancer Therapy-Brain (FACT-Br) Version 4.0</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib, Trastuzumab, Lapatinib and Fulvestrant</intervention_name>
    <description>ER positive, HER2-positive breast cancer patients with brain metastatic lesions receive palbociclib PO daily on days 1-21, combined with trastuzumab IV every three weeks, lapatinib PO daily and fulvestrant IM every 4 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age &gt;18 years old 2. Female patients aged 18 years or older 3. Histologically
             confirmed ER positive, HER2-positive metastatic breast cancer (ER&gt;=1% by IHC; HER-2 3+
             by immunohistochemistry (IHC); if IHC score of 2, fluorescence in situ hybridization
             (FISH) ratio must be greater than 2.0; if FISH less than 2.0, HER2 copy number must be
             greater than 6; NOTE: Brain lesions are not required to have pathologic confirmation)
             4. Patients must have a life expectancy of at least 12 weeks at the time of
             registration 5. Eastern Cooperative Oncology Group (ECOG) performance status &gt;= 2 6.
             Measurable disease in the brain, defined as at least 1 lesion measuring &gt;= 10 mm on
             MRI at the time of registration 7. If patients are on corticosteroids, they must have
             been on a stable or decreasing dose &gt;= 5 days prior to obtaining their baseline
             gadolinium (Gd)-magnetic resonance imaging (MRI) of brain; this MRI is to be obtained
             within 28 days of registration; NOTE: If patient needs escalation of steroids prior to
             therapy, or are on unstable doses of steroids they are not eligible 8. Have completed
             local therapy (surgical resection, WBRT, or SRS) ≥14 days prior to initiating
             palbiciclib and recovered from all acute effects 9. Patients must not have received
             systemic therapy within 2 weeks of initiating palbociclib; NOTE: For patients on
             trastuzumab, they can remain on the drug; no break or washout period required 10.
             Patients must exhibit adequate bone marrow, liver, and renal function, within 14 days
             prior to registration, defined as: a. Absolute neutrophil count (ANC) &gt;= 1,000/mm^3
             (growth factor support is permitted); b. Platelets &gt;= 50,000/mm^3 (may be reached by
             transfusion); c. Hemoglobin &gt;= 10 gm/dl (may be reached by transfusion); d. Glutamate
             pyruvate transaminase (GPT)/glutamate oxaloacetate transaminase (GOT) &lt; 3 x upper
             limit of normal (ULN) (or &lt; 5 x ULN in case of liver metastasis); e. Bilirubin &lt; 3 x
             ULN (or &lt; 5 x ULN in case of liver metastasis); f. Creatinine &lt; 1.5 x ULN 11. Females
             of child-bearing potential (FOCBP) and males must agree to use adequate contraception
             prior to study entry, for the duration of study participation, and for 2 weeks
             following completion of therapy; should a female patient become pregnant or suspect
             she is pregnant while participating in this study, she should inform her treating
             physician immediately; likewise, if the female partner of a male patient becomes
             pregnant while participating in this study, he should inform his treating physician
             immediately; NOTE: A FOCBP is any woman (regardless of sexual orientation, having
             undergone a tubal ligation, or remaining celibate by choice) who meets the following
             criteria: a. Has not undergone a hysterectomy or bilateral oophorectomy; b. Has had
             menses at any time in the preceding 12 consecutive months (and therefore has not been
             naturally postmenopausal for &gt; 12 months) 12. Female patients must have a negative
             urine pregnancy test within 7 days prior to registration; if urine test is positive,
             it should be followed by serum pregnancy test 13. Patients must sign an informed
             consent prior to registration and before undergoing any study-specific procedures
             indicating that they are aware of the investigational nature of this study 14. Patient
             must have the ability to swallow and retain oral medication 15. Patient must have the
             ability to comply with all study requirements

        Exclusion Criteria:

          -  1. Any uncontrolled neurological symptom attributed to CNS metastasis 2. Brain
             metastasis must not be impending herniation or other significant vasogenic edema
             requiring increasing steroid doses; lesions must not have frank hemorrhage 3. Patients
             with leptomeningeal disease are not eligible for participation 4. Any significant
             medical illnesses or infection that, in the investigator's opinion, cannot be
             adequately controlled with appropriate therapy or would compromise the patient's
             ability to tolerate this therapy are not eligible for participation 5. Known human
             immunodeficiency virus (HIV) positive status 6. Known active hepatitis B and/or C 7.
             Patients who have a history of hypersensitivity reaction to one of the compounds or
             incorporated substances used in this protocol; AND/OR patients who have had prior
             exposure to compounds of similar chemical or biologic composition to palbociclib or
             lapatinib are not eligible 8. Patients being treated with any other experimental
             agents/clinical trials are not eligible for participation; if the patient is on any
             investigational agent, a wash-out period of minimum 2 weeks prior to registration is
             mandatory for the patient to be eligible for the study 9. Patients who are on any
             prohibited medication; a wash-out period of minimum 2 weeks prior to registration is
             mandatory for the patient to be eligible for the study 10. Inability to swallow
             capsules, malabsorption syndrome or gastrointestinal disease that severely affects the
             absorption of study drugs, major resection of the stomach or small bowel, or gastric
             bypass procedure 11. Current use or anticipated need for food or drugs that are known
             strong CYP3A4 (cytochrome P450 3A4) inhibitors or inducers 12. Patients who have an
             uncontrolled intercurrent illness including, but not limited to any of the following,
             are not eligible: a. Ongoing or active infection requiring systemic treatment; b.
             Symptomatic congestive heart failure; c. Unstable angina pectoris; d. Cardiac
             arrhythmia: except atrial fibrillation (AF) and supraventricular tachycardia (SVT)
             that are controlled by medication; e. Psychiatric illness/social situations that would
             limit compliance with study requirements; f. Any other illness or condition that the
             treating investigator feels would interfere with study compliance or would compromise
             the patient's safety or study endpoints 13. Female patients who are pregnant or
             nursing are not eligible
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shusen Wang</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>shusen wang, doctor</last_name>
      <phone>8613926168469</phone>
      <email>wangshs@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>fei xu, M.D.</last_name>
      <phone>862087342693</phone>
      <email>xufei@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>wang shusen</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

